A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM

P. Reichardt; D. Pink; T. Lindner; M. C. Heinrich; P. S. Cohen; Y. Wang; R. Yu; A. Tsyrlova; S. Dimitrijevic; C. Blanke

doi:10.1200/jco.2005.23.16_suppl.3016

$A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM$

Journal article

Peer reviewed

A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM

P. Reichardt, D. Pink, T. Lindner, M. C. Heinrich, P. S. Cohen, Y. Wang, R. Yu, A. Tsyrlova, S. Dimitrijevic and C. Blanke

Journal of clinical oncology, Vol.23(16_suppl), pp.3016-3016

06/2005

DOI: https://doi.org/10.1200/jco.2005.23.16_suppl.3016

Abstract

Abstract only

Metrics

1 Record Views

Details

Title: A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM
Creators - without role: P. Reichardt - Charité - Universitätsmedizin Berlin
D. Pink - Charité - Universitätsmedizin Berlin
T. Lindner - Charité - Universitätsmedizin Berlin
M. C. Heinrich - Novartis
P. S. Cohen - Charité - Universitätsmedizin Berlin
Y. Wang - Charité - Universitätsmedizin Berlin
R. Yu - Charité - Universitätsmedizin Berlin
A. Tsyrlova - Charité - Universitätsmedizin Berlin
S. Dimitrijevic - Charité - Universitätsmedizin Berlin
C. Blanke - Charité - Universitätsmedizin Berlin
Publication Details: Journal of clinical oncology, Vol.23(16_suppl), pp.3016-3016
Identifiers: 9934145408331
Academic Unit: King Abdulaziz University
Language: English
Resource Type: Journal article